These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20138510)

  • 1. 2-Amino-aryl-7-aryl-benzoxazoles as potent, selective and orally available JAK2 inhibitors.
    Gerspacher M; Furet P; Pissot-Soldermann C; Gaul C; Holzer P; Vangrevelinghe E; Lang M; Erdmann D; Radimerski T; Regnier CH; Chene P; De Pover A; Hofmann F; Baffert F; Buhl T; Aichholz R; Blasco F; Endres R; Trappe J; Drueckes P
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1724-7. PubMed ID: 20138510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs).
    Burns CJ; Bourke DG; Andrau L; Bu X; Charman SA; Donohue AC; Fantino E; Farrugia M; Feutrill JT; Joffe M; Kling MR; Kurek M; Nero TL; Nguyen T; Palmer JT; Phillips I; Shackleford DM; Sikanyika H; Styles M; Su S; Treutlein H; Zeng J; Wilks AF
    Bioorg Med Chem Lett; 2009 Oct; 19(20):5887-92. PubMed ID: 19762238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and SAR of potent, orally available 2,8-diaryl-quinoxalines as a new class of JAK2 inhibitors.
    Pissot-Soldermann C; Gerspacher M; Furet P; Gaul C; Holzer P; McCarthy C; Radimerski T; Regnier CH; Baffert F; Drueckes P; Tavares GA; Vangrevelinghe E; Blasco F; Ottaviani G; Ossola F; Scesa J; Reetz J
    Bioorg Med Chem Lett; 2010 Apr; 20(8):2609-13. PubMed ID: 20231096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of pyrazol-3-ylamino pyrazines as novel JAK2 inhibitors.
    Ioannidis S; Lamb ML; Davies AM; Almeida L; Su M; Bebernitz G; Ye M; Bell K; Alimzhanov M; Zinda M
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6524-8. PubMed ID: 19857966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis, and evaluation of the anticancer activity of 2-amino-aryl-7-aryl-benzoxazole compounds.
    Khajondetchairit P; Phuangsawai O; Suphakun P; Rattanabunyong S; Choowongkomon K; Gleeson MP
    Chem Biol Drug Des; 2017 Nov; 90(5):987-994. PubMed ID: 28544428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-Aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of JAK2.
    Ledeboer MW; Pierce AC; Duffy JP; Gao H; Messersmith D; Salituro FG; Nanthakumar S; Come J; Zuccola HJ; Swenson L; Shlyakter D; Mahajan S; Hoock T; Fan B; Tsai WJ; Kolaczkowski E; Carrier S; Hogan JK; Zessis R; Pazhanisamy S; Bennani YL
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6529-33. PubMed ID: 19857967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors.
    Wang T; Ledeboer MW; Duffy JP; Salituro FG; Pierce AC; Zuccola HJ; Block E; Shlyakter D; Hogan JK; Bennani YL
    Bioorg Med Chem Lett; 2010 Jan; 20(1):153-6. PubMed ID: 19945871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors.
    Wang T; Ioannidis S; Almeida L; Block MH; Davies AM; Lamb ML; Scott DA; Su M; Zhang HJ; Alimzhanov M; Bebernitz G; Bell K; Zinda M
    Bioorg Med Chem Lett; 2011 May; 21(10):2958-61. PubMed ID: 21493067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole.
    Wang T; Duffy JP; Wang J; Halas S; Salituro FG; Pierce AC; Zuccola HJ; Black JR; Hogan JK; Jepson S; Shlyakter D; Mahajan S; Gu Y; Hoock T; Wood M; Furey BF; Frantz JD; Dauffenbach LM; Germann UA; Fan B; Namchuk M; Bennani YL; Ledeboer MW
    J Med Chem; 2009 Dec; 52(24):7938-41. PubMed ID: 20014869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of potent and highly selective thienopyridine Janus kinase 2 inhibitors.
    Schenkel LB; Huang X; Cheng A; Deak HL; Doherty E; Emkey R; Gu Y; Gunaydin H; Kim JL; Lee J; Loberg R; Olivieri P; Pistillo J; Tang J; Wan Q; Wang HL; Wang SW; Wells MC; Wu B; Yu V; Liu L; Geuns-Meyer S
    J Med Chem; 2011 Dec; 54(24):8440-50. PubMed ID: 22087750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
    Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.
    Weinberg LR; Albom MS; Angeles TS; Breslin HJ; Gingrich DE; Huang Z; Lisko JG; Mason JL; Milkiewicz KL; Thieu TV; Underiner TL; Wells GJ; Wells-Knecht KJ; Dorsey BD
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7325-30. PubMed ID: 22041060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.
    Hanan EJ; van Abbema A; Barrett K; Blair WS; Blaney J; Chang C; Eigenbrot C; Flynn S; Gibbons P; Hurley CA; Kenny JR; Kulagowski J; Lee L; Magnuson SR; Morris C; Murray J; Pastor RM; Rawson T; Siu M; Ultsch M; Zhou A; Sampath D; Lyssikatos JP
    J Med Chem; 2012 Nov; 55(22):10090-107. PubMed ID: 23061660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benzoxazole piperidines as selective and potent somatostatin receptor subtype 5 antagonists.
    Martin RE; Mohr P; Maerki HP; Guba W; Kuratli C; Gavelle O; Binggeli A; Bendels S; Alvarez-Sánchez R; Alker A; Polonchuk L; Christ AD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6106-13. PubMed ID: 19786348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors.
    Costales A; Mathur M; Ramurthy S; Lan J; Subramanian S; Jain R; Atallah G; Setti L; Lindvall M; Appleton BA; Ornelas E; Feucht P; Warne B; Doyle L; Basham SE; Aronchik I; Jefferson AB; Shafer CM
    Bioorg Med Chem Lett; 2014 Mar; 24(6):1592-6. PubMed ID: 24534486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety.
    Smith CJ; Ali A; Chen L; Hammond ML; Anderson MS; Chen Y; Eveland SS; Guo Q; Hyland SA; Milot DP; Sparrow CP; Wright SD; Sinclair PJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):346-9. PubMed ID: 19914065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,5-diarylazoles as novel and selective inhibitors of protein kinase D.
    Gamber GG; Meredith E; Zhu Q; Yan W; Rao C; Capparelli M; Burgis R; Enyedy I; Zhang JH; Soldermann N; Beattie K; Rozhitskaya O; Koch KA; Pagratis N; Hosagrahara V; Vega RB; McKinsey TA; Monovich L
    Bioorg Med Chem Lett; 2011 Mar; 21(5):1447-51. PubMed ID: 21300545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of orally active benzimidazoles and benzoxazoles as vascular endothelial growth factor-2 receptor tyrosine kinase inhibitors.
    Potashman MH; Bready J; Coxon A; DeMelfi TM; DiPietro L; Doerr N; Elbaum D; Estrada J; Gallant P; Germain J; Gu Y; Harmange JC; Kaufman SA; Kendall R; Kim JL; Kumar GN; Long AM; Neervannan S; Patel VF; Polverino A; Rose P; Plas Sv; Whittington D; Zanon R; Zhao H
    J Med Chem; 2007 Sep; 50(18):4351-73. PubMed ID: 17696416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SAR and in vivo evaluation of 4-aryl-2-aminoalkylpyrimidines as potent and selective Janus kinase 2 (JAK2) inhibitors.
    Forsyth T; Kearney PC; Kim BG; Johnson HW; Aay N; Arcalas A; Brown DS; Chan V; Chen J; Du H; Epshteyn S; Galan AA; Huynh TP; Ibrahim MA; Kane B; Koltun ES; Mann G; Meyr LE; Lee MS; Lewis GL; Noguchi RT; Pack M; Ridgway BH; Shi X; Takeuchi CS; Zu P; Leahy JW; Nuss JM; Aoyama R; Engst S; Gendreau SB; Kassees R; Li J; Lin SH; Martini JF; Stout T; Tong P; Woolfrey J; Zhang W; Yu P
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7653-8. PubMed ID: 23127890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and SAR of new pyrazolo[4,3-h]quinazoline-3-carboxamide derivatives as potent and selective MPS1 kinase inhibitors.
    Caldarelli M; Angiolini M; Disingrini T; Donati D; Guanci M; Nuvoloni S; Posteri H; Quartieri F; Silvagni M; Colombo R
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4507-11. PubMed ID: 21723120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.